Stockscreener 앱 받기
0.2458
1.25%
-0.0031
시장 영업 전:
.24
-0.0058
-2.36%
전일 마감가:
$0.2489
열려 있는:
$0.2515
하루 거래량:
3.47M
Relative Volume:
1.95
시가총액:
$10.09M
수익:
$1.04M
순이익/손실:
$-67.50M
주가수익비율:
-0.1279
EPS:
-1.9222
순현금흐름:
$-60.67M
1주 성능:
-67.66%
1개월 성능:
-54.81%
6개월 성능:
-65.94%
1년 성능:
-87.71%
1일 변동 폭
$0.2362
$0.2572
1주일 범위
$0.198
$0.2664
52주 변동 폭
$0.198
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.2458 | 9.27M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-12-17 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 개시 | Jefferies | Buy |
| 2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Ther - The National Law Review
symbol__ Stock Quote Price and Forecast - CNN
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell - Stocktwits
VistaGen Therapeutics, Inc. (VTGN) announced topline data and post-hoc analysis results from the Phase 3 clinical trial Palisade-4 of its candidate drug Fasedienol for the acute treatment of social anxiety disorder. - Bitget
Vistagen (VTGN) Reports Phase 3 Trial Results for Fasedienol - GuruFocus
VTGN: Post-hoc analyses show fasedienol benefits very severe social anxiety, guiding a new LSAS-based trial - TradingView
Vistagen reports PALISADE-4 miss on primary endpoints; positive post-hoc signal in very severe SAD subgroup - TradingView
Vistagen (NASDAQ: VTGN) Phase 3 fasedienol trial misses main goal but shows severe-SAD signal - Stock Titan
Vistagen’s fasedienol fails main test, but one subgroup showed a signal - Stock Titan
Vistagen Therapeutics, Inc. Actuals & Estimates (NASDAQ:VTGN) - TradingView
Vistagen Therapeutics, Inc. Actuals & Estimates (BMV:VTGN) - TradingView
Vistagen Therapeutics, Inc. Actuals & Estimates (BOATS:VTGN) - TradingView
VTGN Forecast — Price Target — Prediction for 2027 - TradingView
Vistagen Therapeutics Inc (VTGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth - The Globe and Mail
Vistagen Therapeutics directors to step down after 2026 annual meeting - Investing.com UK
Vistagen Therapeutics directors to step down after 2026 annual meeting By Investing.com - Investing.com India
Vistagen Therapeutics Inc (VTGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vistagen Therapeutics Inc (VTGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Two Vistagen (VTGN) directors will not seek re-election at 2026 shareholder meeting - Stock Titan
Vistagen Therapeutics Inc (VTGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vistagen Therapeutics Inc (VTGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vistagen Therapeutics Inc (VTGN) Institutional Confidence - TradingKey
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - BioSpace
VistaGen Therapeutics (VTGN) Q4 2026 earnings summary - Quartr
VISTAGEN THERAPEUTICS ($VTGN) Releases Q4 2026 Earnings - Quiver Quantitative
vtgn-20260331 - SEC.gov
VTGN: Net loss increased to $69.7M as R&D spending rose, with cash reserves at $45.4M and going concern risk - TradingView
Vistagen (VTGN) outlines Phase 3 fasedienol data and broad intranasal CNS pipeline - Stock Titan
Vistagen Reports FY2026 Net Loss $69.7M; Cash and Marketable Securities $45.4M - TradingView
VTGN: Advanced clinical milestones and maintained cash runway despite increased net loss - TradingView
Vistagen (NASDAQ: VTGN) advances fasedienol trials as FY 2026 loss deepens - Stock Titan
Press Release: Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - Moomoo
Generalized Anxiety Disorder Market: Growth Momentum Across 7MM to 2036 – DelveInsight | VistaGen Therapeutics, Fabre-Kramer Pharm, Mind Med, Sunovion, ChemRar Research, Biohaven Pharma, Forest Lab - Barchart.com
Vistagen Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
VTGN Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Edges HigherGuidance vs Actual - newsline.com
VTGN News | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Vistagen Therapeutics (VTGN) Edges Higher Amid Cautious TradingRVOL Breakout - newsline.com
Vistagen (VTGN) Achieves Key Milestone in Social Anxiety Disorder Treatment - GuruFocus
Vistagen achieves ICH E1 safety exposure milestones for fasedienol; >1,500 subjects exposed - TradingView
Vistagen (VTGN) reaches ICH safety exposure goal in Phase 3 fasedienol program - Stock Titan
Vistagen meets ICH E1 safety exposure targets for fasedienol By Investing.com - Investing.com Australia
Nasal spray for social anxiety clears key safety bar in 1,500 people - Stock Titan
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm - GuruFocus
Vistagen Stock at 63 Cents: The June Trial Readout Traders Are Watching - Bez Kabli
VTGN Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost DisciplineEPS Revision Trend - The Legal Advocate
Vistagen (VTGN) Prepares for Jefferies Healthcare Conference Ami - GuruFocus
Vistagen (VTGN) Prepares for Jefferies Healthcare Conference Amid Key Trial Updates - GuruFocus
Investor meetings as Vistagen joins Jefferies 2026 healthcare event in NYC - Stock Titan
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
0.74%
자본화:
|
볼륨(24시간):